Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Emergent BioSolutions Jumped Higher on Tuesday

By Brian Orelli, PhD - Mar 10, 2020 at 6:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company added its name to the long list of companies helping develop a vaccine to the coronavirus that causes COVID-19.

What happened

Shares of Emergent BioSolutions (EBS 0.00%) jumped 10.2% on Tuesday after the bioterrorism expert said that it's working with Novavax (NVAX 2.00%) to develop its vaccine against the coronavirus that causes COVID-19.

So what

The announcement shouldn't have come as much of a surprise. On its fourth-quarter conference call last month, Emergent's president and CEO, Robert Kramer, said the company was in talks with the U.S. government, non-governmental organizations, and other companies to see how Emergent could use its resources and expertise to help develop a vaccine, treatment, or diagnostic for COVID-19.

Emergent is known for manufacturing its own products, many of which are purchased by the government and stockpiled in case of an attack or emergence of an infectious disease, but the company also has a contract manufacturing business where it makes products for other drugmakers.

Hands giving a shot in someone's shoulder

Image source: Getty Images.

Now what

While the contract is good news for Emergent BioSolutions, the company didn't provide financial details for the contract, so it's impossible for investors to know how much Emergent will benefit from producing Novavax's vaccine. For reference, last year, Emergent brought in $80 million from its contract development and manufacturing services, which was 7.2% of total revenue. https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-reports-financial-results-fourth-quarter-1?field_nir_news_date_value[min]=

Even if we did know how much Emergent was making per dose of the vaccine, it would still be very difficult to anticipate how much Emergent would profit from the contract because there are multiple drug companies developing vaccines for the coronavirus, including some who are ahead of Novavax. Of course, give that almost every human on the planet will want a vaccine, the companies are likely to be supply constrained, so not being first to market may not be a major issue.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
EBS
$30.50 (0.00%) $0.00
Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$42.30 (2.00%) $0.83

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.